Clinical Trials Directory

Duke will give patients three special inhalers called Airsupra to use when they need help breathing. Normally, patients use an inhaler called albuterol, but in this study, some patients will use Airsupra instead. After leaving the emergency room, the study team will check on patients at about 3, 6, and 12 weeks to see how they are doing and if they have any problems with their inhaler. Most check-ins will be by phone, but email may be used if the patient prefers or to make sure all information is collected.

In the first part of the study, some people will get a new medicine called maridebart cafraglutide. They will get small shots that slowly increase in amount over 16 weeks. Other people will get a fake medicine called a placebo, but the shots will look the same. After this first part, people who stay in the study can join the second part. In this part, everyone will get the real medicine for about 2 years. Doctors will keep checking to see how well the medicine works and if it is safe.

We are doing this study to find out if an experimental CAR-T cell therapy called MB-CART2019.1 (the study drug) may help eliminate cancer cells in patients who have relapsed or refractory DLBCL. The study drug will be combined with fludarabine and cyclophosphamide, which are both standard drugs used to treat DLBCL.

We are doing this study to learn more about the safety and performance of heart valve repair and replacement products made by Medtronic.

We are doing this study to keep tabs on the health status of people who have used, or who plan to use, a Medtronic® medical device to treat a urological or digestive disorder. This study is a registry, which means that it will allow us to compile information about how well these products work and how well they improve patients' quality of life.

We are doing this study to look at blood, tumor, and lymph node tissue from people with melanoma so we can improve diagnostic methods and therapies for people with melanoma.

We are doing this study to learn more about the symptoms of menopause in women with sickle cell disease (SCD). We want to learn more about how hydroxyurea, pain, and other SCD-related complications can affect their menopause experience. We hope this study can help us more quickly and easily find out when women with SCD might be experiencing health complications related to menopause.

We are doing this study to find the most effective, safe dose of an experimental drug called bomedemstat (the study drug) for people with essential thrombocythemia who are unable to take hydroxyurea or do not get a benefit from it.